1. Krause KM, Serio AW, Kane TR, Connolly LE. Aminoglycosides: An Overview. Cold Spring Harb Perspect Med. 2016 Jun 1;6(6):a027029.
2. PubChem. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2023. PubChem Compound Summary for CID 36294, Tobramycin. https://pubchem.ncbi.nlm.nih.gov/compound/Tobramycin
4. Takahashi Y, Igarashi M. Destination of aminoglycoside antibiotics in the 'post-antibiotic era'. J Antibiot (Tokyo). 2017 Oct 25.
8. US Food and Drugs Administration. Tobramycin for Injection. 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050789s005lbl.pdf
9. Drugs.com. Tobramycin (Inhalation). 2021. https://www.drugs.com/mtm/tobramycin-inhalation.html
10. Vicens Q, Westhof E. RNA as a drug target: the case of aminoglycosides. Chembiochem. 2003 Oct 6;4(10):1018-23.
11. Krause KM, Serio AW, Kane TR, Connolly LE. Aminoglycosides: An Overview. Cold Spring Harb Perspect Med. 2016 Jun 1;6(6):a027029.
12. Craig WA. Optimizing aminoglycoside use. Crit Care Clin. 2011 Jan;27(1):107-21.
13. Garneau-Tsodikova S, Labby KJ. Mechanisms of Resistance to Aminoglycoside Antibiotics: Overview and Perspectives. Medchemcomm. 2016 Jan 1;7(1):11-27.
14. Padmasini E, Padmaraj R, Ramesh SS. High level aminoglycoside resistance and distribution of aminoglycoside resistant genes among clinical isolates of Enterococcus species in Chennai, India. ScientificWorldJournal. 2014 Feb 4;2014:329157.